semaglutide tirzepatide vs. Semaglutide: Which Weight Loss Medication Is Right for You? Semaglutide vs Tirzepatide: Which Is

Oral semaglutide was then investigated in eight global Peptide InnOvatioN for the Early diabEtes tReatment (PIONEER) phase IIIa trials in over 8,000 patients, with similarly broad evaluation in different patient populations who were receiving a range of background medications (2633) ( Table 1 )

Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon

Long-term outcomes over 6 to 12 months show average total weight loss of 10 to 15 percent of body weight in clinical trials, with some patients losing 20 to 22 percent

A clinically relevant effect will depend on the extent of PK changes and the therapeutic index of the co-administered oral drug

[DOI] [PubMed] [Google Scholar] 320.Lim G.E., Brubaker P.L